Core Viewpoint - Tai Long Pharmaceutical (600222.SH) reported a decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The total operating revenue for the first three quarters reached 1.187 billion yuan, a year-on-year decrease of 11.47% [1] - The net profit attributable to shareholders was 25.3255 million yuan, down 12.36% year-on-year [1] - Basic earnings per share were reported at 0.0458 yuan [1] Dividend Announcement - The company plans to distribute a cash dividend of 0.14 yuan (including tax) for every 10 shares to all shareholders [1]

Group 1 - The core point of the article is that Tai Long Pharmaceutical reported its Q3 2025 financial results, showing a revenue increase and a significant rise in net profit [1] Group 2 - In Q3 2025, the company achieved a revenue of 424,470,623.44 yuan, representing a year-on-year growth of 2.67% [1] - The net profit attributable to shareholders of the listed company was 5,978,861.00 yuan, reflecting a substantial year-on-year increase of 162.48% [1]

关于拟申请注册发行中期票据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 河南太龙药业股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开第十届董事会第四次会议，审议通过了《关于拟申请注 册发行中期票据的议案》。为进一步拓宽融资渠道，增加债务融资的 多样性与灵活性，优化融资结构，根据《公司法》《银行间债券市场 非金融企业债务融资工具管理办法》等相关规定，并结合公司实际情 况，公司拟向中国银行间市场交易商协会（以下简称"交易商协会"） 申请注册发行总额不超过人民币 6 亿元（含）的中期票据，具体情况 如下： 一、本次中期票据发行方案的主要内容 （一）注册和发行规模：拟注册发行规模不超过人民币 6 亿元 （含），具体发行规模将以公司在交易商协会注册的金额为准。 （二）发行期限：不超过 5 年（含）。 （三）发行方式：在批准的注册额度及有效期内一次或分期发行。 （四）资金用途：用于补充营运资金、置换金融机构借款和到期 债务融资工具及交易商协会认可的其他用途。 （五）发行利率：根据发行时银行间债券市场的实际 ...

证券代码：600222 证券简称：太龙药业 公告编号：临 2025-056 河南太龙药业股份有限公司 关于召开 2025 年第三季度业绩 暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 07 日(星期五)11:00-12:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 31 日（星期五）至 11 月 06 日（星 期四）16:00 期间登录上证路演中心网站首页点击"提问预征集"栏 目 进 行 提 问 ， 或 将 问 题 以 电 子 邮 件 形 式 发 送 至 公 司 邮 箱 600222@taloph.com。公司将在说明会上对投资者普遍关注的问题进 行回答。 河南太龙药业股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日发布公司《2025 年第三季度报告》和《2025 年前三季度 利润分配 ...

证券代码：600222 证券简称：太龙药业 公告编号：2025-055 河南太龙药业股份有限公司 关于召开2025年第四次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东会类型和届次 2025年第四次临时股东会 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方 式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 11 月 14 日 14 点 30 分 召开地点：郑州市高新技术产业开发区金梭路 8 号公司一楼会议室 (五)网络投票的系统、起止日期和投票时间。 股东会召开日期：2025年11月14日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 11 月 14 日 至2025 年 11 月 14 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段， ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600222 证券简称：太龙药业 公告编号：临 2025-052 河南太龙药业股份有限公司 第十届董事会第四次会议决议公告 一、董事会会议召开情况 河南太龙药业股份有限公司（以下简称"公司"）第十届董事会 第四次会议于 2025 年 10 月 28 日上午在公司一楼会议室以现场结合 通讯的方式召开。会议通知已于 2025 年 10 月 23 日送达各位董事。 本次会议应出席董事 9 人，实际出席董事 9 人，其中副董事长李景亮 先生、独立董事方亮先生以通讯方式出席。会议由董事长王荣涛先生 召集并主持。会议的召集、召开及表决程序等符合有关法律、法规和 《公司章程》的规定，所作决议合法有效。 二、董事会会议审议情况 公司拟以实施权益分派股权登记日登记的总股本(扣除回购专户 的股份)为基数向全体股东每 10 股派发现金红利 0.14 元（含税）, 不 送红股，不以公积金转增股本。 （一）审议通过《公司 2025 年第三季度报告》 本议案在提交董事会审议前已经审计委员会事先审议 ...

河南太龙药业股份有限公司 2025 年前三季度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 ： 分配比例：每10股派发现金红利0.14元（含税），不送红股， 不以公积金转增股本。 证券代码：600222 证券简称：太龙药业 公告编号：临 2025-053 本次利润分配以实施权益分派股权登记日登记的总股本(扣除 回购专户的股份)为基数，具体日期将在权益分派实施公告中明确； 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股 分配比例不变，相应调整利润分配总额，并将另行公告具体调整情况。 本议案已经公司第十届董事会第四次会议审议通过，尚需提交 公司股东会审议。 一、 利润分配方案内容 河南太龙药业股份有限公司（以下简称"公司"）2025 年 1-9 月 实现归属于母公司股东的净利润 25,325,461.25 元（未经审计），截 至2025年9月30日母公司报表中期末未分配利润为107,463,112.44 元（未经审计）。 为促进全体股东共享公司经营发展成果，经综合考虑公司经营盈 利状 ...

Financial Performance - The company's operating revenue for Q3 2025 was CNY 424,470,623.44, representing a year-on-year increase of 2.67%[4] - The total profit for the period reached CNY 9,941,768.63, a significant increase of 273.79% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 5,978,861.00, up 162.48% year-on-year, while the net profit after deducting non-recurring gains and losses was CNY 5,536,316.03, an increase of 190.64%[4] - The total revenue for the company was CNY 1,183,897,627.30, representing an 11.43% decrease year-over-year, with an overall gross margin of 24.22%[12] - Total operating revenue for the first three quarters of 2025 was ¥1,186,902,173.45, a decrease of 11.43% compared to ¥1,340,673,177.46 in the same period of 2024[19] - Net profit for the first three quarters of 2025 was ¥30,474,636.07, slightly up from ¥29,947,526.30 in 2024, representing an increase of 1.76%[20] - The company achieved a gross profit of ¥19,928,305.84 in the first three quarters of 2025, compared to a gross profit of ¥294,629,217.40 in 2024, indicating a significant decline[19] - The total comprehensive income for the first three quarters of 2025 was ¥10,245,764.13, a decrease from ¥24,167,937.53 in 2024[20] Assets and Liabilities - The company's total assets increased by 7.12% to CNY 3,738,301,973.19 compared to the end of the previous year[5] - As of September 30, 2025, the company's total assets amounted to CNY 3,738,301,973.19, an increase from CNY 3,489,768,020.93 at the end of 2024[14] - The company's current assets totaled CNY 2,198,942,152.62, up from CNY 1,906,060,559.97 at the end of 2024[14] - The total liabilities increased to CNY 2,088,811,617.38 from CNY 1,863,525,871.55 in the previous year[16] - The company's cash and cash equivalents rose to CNY 343,860,135.43, compared to CNY 180,039,805.83 at the end of 2024[14] - Cash and cash equivalents at the end of the first three quarters of 2025 totaled ¥318,713,235.45, compared to ¥329,443,242.18 at the end of the same period in 2024[25] Shareholder Information - The top shareholder, Zhengzhou Tai Rong Industrial Investment Co., Ltd., holds 14.37% of the shares, with 41,220,584 shares pledged[9] - The company has a total of 40,442 common shareholders as of the end of the reporting period[9] Business Segments - The main business segment, pharmaceutical preparations, faced a decline in sales revenue due to incomplete coverage of national traditional Chinese medicine procurement and price reductions[11] - The total revenue for the pharmaceutical preparation segment was CNY 226,792,579.87, a decrease of 37.73% compared to the previous year, with a gross margin of 42.39%[12] - The revenue from traditional Chinese medicine pieces was CNY 611,281,775.45, down 8.75% year-over-year, with a gross margin of 17.22%[12] - The pharmaceutical R&D services generated revenue of CNY 164,566,927.79, reflecting a decline of 25.43% from the previous year, with a gross margin of 34.87%[12] - The pharmaceutical materials circulation segment saw a significant revenue increase of 121.13% to CNY 181,256,344.19, with a gross margin of 15.38%[12] Cash Flow and Financing - The company reported a net cash flow from operating activities of CNY -88,989,041.18, reflecting a decrease of 7.99% year-on-year[4] - The company reported a net cash flow from operating activities of -¥88,989,041.18 for the first three quarters of 2025, an improvement from -¥96,714,807.67 in 2024[24] - The company issued a short-term financing bond totaling CNY 400 million at an annual interest rate of 2.80% on September 25, 2025[13] Research and Development - Research and development expenses for the first three quarters of 2025 were ¥38,101,656.16, a decrease of 50.7% from ¥77,116,859.71 in 2024[19] Earnings Per Share - Basic and diluted earnings per share for the first three quarters of 2025 were both ¥0.0458, down from ¥0.0519 in 2024[20] Investment Income - The company reported an investment income loss of ¥265,270.00 in the first three quarters of 2025, compared to a gain of ¥1,051,330.44 in 2024[19]

Core Viewpoint - The announcement from Henan Tailong Pharmaceutical Co., Ltd. indicates that over 5% shareholder Zhengzhou Zhongsheng Industrial Group Co., Ltd. has had its shares frozen and marked for judicial purposes, which may pose investment risks for stakeholders [2][3]. Group 1: Shareholder Information - Zhengzhou Zhongsheng holds 50,000,000 unrestricted tradable shares, all of which are currently pledged, representing 8.71% of the company's total share capital [2]. - As of the announcement date, all of Zhongsheng's shares (50,000,000) are frozen or marked for judicial purposes, accounting for 100% of its holdings [2][3]. Group 2: Legal and Financial Context - The shares were pledged in November 2016, and the judicial marking is due to financial loan contract disputes, with claims amounting to 35 million yuan and 284.51 million yuan respectively [3][4]. - The company clarifies that Zhongsheng is not the controlling shareholder, and this situation will not lead to a change in control of the company [3][5]. Group 3: Company Operations and Future Actions - The company will continue to monitor the situation and will fulfill its information disclosure obligations as necessary [5][6].

Group 1 - The core point of the article is that Tai Long Pharmaceutical has announced that all of its shares held by Zhongsheng Industrial, totaling 50 million shares, have been frozen and marked for judicial purposes, which constitutes 100% of Zhongsheng's holdings in the company [1] - As of the announcement date, Tai Long Pharmaceutical's market capitalization is 3.8 billion yuan [1] - For the first half of 2025, the revenue composition of Tai Long Pharmaceutical is as follows: 70.59% from pharmaceutical manufacturing, 14.71% from pharmaceutical research and development, 14.42% from pharmaceutical distribution, and 0.28% from other businesses [1]